Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience Meeting Abstract


Authors: Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; Smyth, L.; Norton, L.; Baselga, J.; Hudis, C.; Dang, C.
Abstract Title: Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
Meeting Title: 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Journal Title: Cancer Research
Volume: 76
Issue: 4 Suppl.
Meeting Dates: 2015 Dec 8-12
Meeting Location: San Antonio, TX
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2016-02-15
Language: English
ACCESSION: WOS:000375622400335
DOI: 10.1158/1538-7445.sabcs15-p1-14-17
PROVIDER: wos
Notes: Meeting Abstract: P1-14-17 -- Source: Wos
Altmetric Score
MSK Authors
  1. Sujata Patil
    386 Patil
  2. Clifford Hudis
    848 Hudis
  3. Larry Norton
    581 Norton
  4. Chau Dang
    161 Dang
  5. Shanu Modi
    134 Modi
  6. Neil Mukund Iyengar
    63 Iyengar
  7. Anthony Yu
    37 Yu
  8. Jose T Baselga
    410 Baselga
  9. Lee Winston Jones
    107 Jones
  10. Jasmeet Chadha Singh
    11 Singh
  11. Lillian   Smyth
    20 Smyth